# To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older

> **NCT00082095** · PHASE3 · TERMINATED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 62 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Pegylated liposomal doxorubicin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT00082095
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-04
- **Primary completion:** 2005-12
- **Final completion:** 2005-12
- **Target enrollment:** 62 (ACTUAL)
- **Why stopped:** The study was terminated due to poor recruitment (after enrolling 62 of planned 300 patients in 20 months
- **Last updated:** 2014-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00082095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00082095, "To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00082095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*